Zydus Lifesciences Reports Q2 FY27 Results with 29% Revenue Growth
Zydus Lifesciences Ltd 路 Press Release 路 04 Nov 2026, 6:10 pm
Zydus Lifesciences Reports Q2 FY27 Results with 29% Revenue Growth Zydus Lifesciences reported consolidated revenue of Rs. 79,096 mn for Q2 FY27, up 29.2% YoY, supported by India Formulations (+18.3% YoY to Rs. 18,844 mn) and North America Formulations (+20.8% YoY to Rs. 33,145 mn). EBITDA declined 6.0% YoY to Rs. 18,945 mn, with margins contracting to 24.0% from 32.9% in Q2 FY26. Net profit dropped 26.6% YoY to Rs. 9,255 mn. R&D investments stood at Rs. 6,573 mn (8.3% of revenues). Net debt to EBITDA reached 0.62x as of 30th Sep'26.
Original exchange filing (PDF)
More announcements from Zydus Lifesciences Ltd
- Press Release 路 14 Nov 2026
- Completion of transaction 路 12 Nov 2026
- Transcript of the post results earnings call held on November 4, 2026. 路 07 Nov 2026
- Press Release 路 07 Nov 2026
- The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Life Insurance Corporation of India 路 06 Nov 2026
- Investor Conference 路 06 Nov 2026
- Audio recording of the Company's Investor Call 路 05 Nov 2026
- Investor presentation 路 04 Nov 2026
